Understanding and modulating mammalian-microbial communication for improved human health

Area of Science:

• Microbiology
• Human Physiology
• Pharmacology

Background:

• The symbiotic role of gastrointestinal (GI) bacteria has been recognized since 1885.
• Microbes are involved in the biotransformation of therapeutic compounds, including early sulfa drugs.
• The Human Microbiome Project (completed in 2012) advanced our understanding of mammalian-microbial communication.

Purpose of the Study:

• To review biochemical pathways between commensal GI bacteria and mammalian systems.
• To explore the impact of microbiota on inflammation, immunology, metabolism, and neurobiology.
• To discuss modulation of microbial drug biotransformation for improved therapeutic outcomes.

Main Methods:

• Review of existing literature on GI microbiota and host interactions.
• Analysis of biochemical pathways involved in mammalian-microbial communication.
• Examination of microbial biotransformation of therapeutic agents.

Main Results:

• Commensal GI bacteria engage in complex biochemical crosstalk with local epithelia and systemic mammalian functions.
• Microbiota influences key physiological processes including inflammation, immunity, metabolism, and neurobiology.
• Microbial metabolism significantly affects the efficacy and toxicity of various drugs.

Conclusions:

• The intricate biochemical interactions between the gut microbiota and the host are crucial for maintaining health.
• Targeting microbial biotransformation pathways offers a promising strategy to enhance drug safety and effectiveness.
• Further research into the mammalian-microbial axis is essential for advancing personalized medicine.